# US 2017/0285025 A1 · Compositions, methods and kits to detect herpes simplex virus nucleic acids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0285025 A1
- Document ID: US20170285025A1
- Status: Published application
- Kind: A1
- Application number: 15/487,240
- Filed: 2017-04-13
- Published: 2017-10-05
- Earliest claimed: 2012-04-24
- Assignees: Gen-Probe Incorporated
- Applicants: Gen-Probe Incorporated
- Inventors: Damon K. GETMAN; Aparna AIYER
- Web page: https://patentgrep.com/patent/US20170285025A1

## CPC

- G01N 33/569: for microorganisms, e.g. protozoa, bacteria, viruses
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 39/245: Herpetoviridae, e.g. herpes simplex virus
- C07K 14/035: Herpes simplex virus I or II
- C07K 16/08: against material from viruses
- C12N 15/09: Recombinant DNA-technology
- C12Q 1/705: {for herpetoviridae, e.g. herpes simplex, varicella zoster}
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 45/00: Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The disclosed invention is related to methods, compositions, kits and isolated nucleic acid sequences for targeting Herpes Simplex Virus (HSV) nucleic acid (e.g., HSV-1 and/or HSV-2 nucleic acid). Compositions include amplification oligomers, detection probe oligomers and/or target capture oligomers. Kits and methods comprise at least one of these oligomers.

## Claims

### Claim 1

A method for determining the presence or absence of Herpes Simplex Virus 2 (HSV-2) in a sample, said method comprising:
(1) contacting a sample, said sample suspected of containing HSV-2, with at least two oligomers for amplifying a target region of an HSV-2 target nucleic acid, wherein the at least two amplification oligomers comprise (a) a first amplification oligomer comprising a first target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides (i) contained in the sequence of SEQ ID NO:49 and that includes at least the sequence of SEQ ID NO:48 or (ii) contained in the sequence of SEQ ID NO:43 and that includes at least the sequence of SEQ ID NO:42; and
(b) a second amplification oligomer comprising a second target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides (i) contained in the sequence of SEQ ID NO:51 and that includes at least the sequence of SEQ ID NO:50 or (ii) contained in the sequence of SEQ ID NO:45 and that includes at least the sequence of SEQ ID NO:44;
(2) performing an in vitro nucleic acid amplification reaction, wherein any HSV-2 target nucleic acid present in said sample is used as a template for generating an amplification product; and
(3) detecting the presence or absence of the amplification product, thereby indicating the presence or absence of HSV-2 in said sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein
the first target hybridizing sequence is contained in the sequence of SEQ ID NO:49 and includes at least the sequence of SEQ ID NO:48; and
the second target hybridizing sequence is contained in the sequence of SEQ ID NO:51 and includes at least the sequence of SEQ ID NO:50.

### Claim 3 (depends on 2)

The method of claim 2, wherein the first target-hybridizing sequence has the sequence of SEQ ID NO:24.

### Claim 4 (depends on 2)

The method of claim 2, wherein the second target hybridizing sequence has the sequence of SEQ ID NO:25.

### Claim 5 (depends on 1)

The method of claim 1, wherein
the first target hybridizing sequence is contained in the sequence of SEQ ID NO:43 and includes at least the sequence of SEQ ID NO:42; and
the second target hybridizing sequence is contained in the sequence of SEQ ID NO:45 and includes at least the sequence of SEQ ID NO:44.

### Claim 6 (depends on 5)

The method of claim 5, wherein the first target-hybridizing sequence has the sequence of SEQ ID NO:14.

### Claim 7 (depends on 5)

The method of claim 5, wherein the second target hybridizing sequence has the sequence of SEQ ID NO:15.

### Claim 8 (depends on 1)

The method of claim 1, wherein the first and second target-hybridizing sequences respectively have the nucleotide sequences of
(i) SEQ ID NO:24 and SEQ ID NO:25; or
(ii) SEQ ID NO:14 and SEQ ID NO:15.

### Claim 9 (depends on 1)

The method of claim 1, wherein the first amplification oligomer is a promoter primer or promoter provider further comprising a promoter sequence located 5′ to the first target-hybridizing sequence.

### Claim 10 (depends on 9)

The method of claim 9, wherein the promoter sequence is a T7 promoter sequence.

### Claim 11 (depends on 10)

The method of claim 10, wherein the promoter sequence has the sequence of SEQ ID NO: 54.

### Claim 12 (depends on 11)

The method of claim 11, wherein the first amplification oligomer has a sequence selected from the group consisting of SEQ ID NO:23 and SEQ ID NO:13.

### Claim 13 (depends on 1)

The method of claim 1, further comprising purifying the HSV-2 target nucleic acid from other components in the sample before step (1).

### Claim 14 (depends on 13)

The method of claim 13, wherein the purifying step comprises contacting the sample with at least one capture probe oligomer comprising (i) a target-hybridizing sequence covalently attached to a sequence or moiety that binds to an immobilized probe, wherein said target-hybridizing sequence is selected from the group consisting of SEQ ID NO:4, SEQ ID NO:18, SEQ ID NO:70, and SEQ ID NO:72; or (ii) a sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:17, SEQ ID NO:69, and SEQ ID NO:71; or (iii) a target-hybridizing sequence covalently attached to a sequence or moiety that binds to an immobilized probe, wherein said target-hybridizing sequence is from about 15 to about 30 contiguous nucleotides contained in the sequence of SEQ ID NO:76 and includes at least the sequence of SEQ ID NO:75; or (iv) a target-hybridizing sequence the is contained in the sequence of SEQ ID NO:74; or (v) a target-hybridizing sequence that is contained in the sequence of SEQ ID NO:74 and includes at least the sequence of SEQ ID NO:75.

### Claim 15 (depends on 1)

The method of claim 1, wherein the detecting step (3) comprises contacting said in vitro nucleic acid amplification reaction with a detection probe oligomer configured to specifically hybridize to the amplification product under conditions whereby the presence or absence of the amplification product is determined, thereby indicating the presence or absence of HSV-2 in said sample.

### Claim 16 (depends on 15)

The method of claim 15, wherein the detection probe oligomer comprises (i) a target-hybridizing sequence that is from about 14 to about 25 nucleotides in length and is configured to specifically hybridize to a target sequence contained within SEQ ID NO:2 from about nucleotide position 608 to about nucleotide position 632; or (ii) a target-hybridizing sequence that is contained in the sequence of SEQ ID NO:53 and includes at least the sequence of SEQ ID NO:52; or (iii) a target-hybridizing sequence consisting of SEQ ID NO:27; or (iv) a target-hybridizing sequence that is from about 14 to about 30 nucleotides in length and is configured to specifically hybridize to a target sequence contained within SEQ ID NO:2 from about nucleotide position 549 to about nucleotide position 578; or (v) a target-hybridizing sequence that is contained in the sequence of SEQ ID NO:47 and includes at least the sequence of SEQ ID NO:46; or (vi) a target-hybridizing sequence consisting of SEQ ID NO:16.

### Claim 17 (depends on 16)

The method of claim 16, wherein the detection probe further comprises a label; preferably a chemiluminescent label or a fluorescent label; more preferably a fluorescent label and a quencher.

### Claim 18 (depends on 16)

The method of claim 16, wherein the detection probe further comprises a non-target-hybridizing sequence.

### Claim 19

A combination of at least two oligomers for determining the presence or absence of Herpes Simplex Virus 2 (HSV-2) in a sample, said oligomer combination comprising:
first and second amplification oligomers for amplifying a target region of an HSV-2 target nucleic acid, wherein
(a) the first amplification oligomer comprises a first target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides (i) contained in the sequence of SEQ ID NO:49 and that includes at least the sequence of SEQ ID NO:48 or (ii) contained in the sequence of SEQ ID NO:43 and that includes at least the sequence of SEQ ID NO:42; and
(b) the second amplification oligomer comprises a second target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides (i) contained in the sequence of SEQ ID NO:51 and that includes at least the sequence of SEQ ID NO:50 or (ii) contained in the sequence of SEQ ID NO:45 and that includes at least the sequence of SEQ ID NO:44.

### Claim 20 (depends on 1)

A reaction mixture comprising the combination of at least two oligomers as in claim 1.
